February 2026
We are excited to welcome Dr. Partho Halder as our new Head of Research & Development.
Dr. Halder joins QUESTALPHA after many years in leadership roles at CSL Behring spanning across R&D, GMP, and industrial reality. Most recently, he led multidisciplinary teams in AS&T (Analytical Science & Technology), shaping bioanalytical solutions that are not just scientifically sound - but truly fit for real-world use.
His background spans bio analytics, recombinant technologies, analytical method development, and GMP quality control. What stands out most is his ability to turn complex science into robust, scalable solutions - a skill that matters deeply in MedTech and Life Sciences.
Before industry, Dr. Halder built his scientific foundation at the Max Planck Institute and earned his PhD from the University of Wuerzburg, Germany focusing on translational research.
At QUESTALPHA, he will help us in shaping the next phase of our R&D journey - with a clear focus on Wound Care by combining advancements in material sciences and life sciences to deliver innovative and qualitative solutions with clinical relevance. His appointment reflects our long-term commitment to strong R&D leadership, regulatory ready innovation, and sustainable MedTech solutions.
Welcome to QUESTALPHA, Dr. Halder. We are glad to have you on board.